The $400K insider bridge loan signals acute near-term cash needs for this micro-cap. Monitor for a dilutive equity offering (targeting $5M+) which would trigger conversion and dilute existing holders. The CEO's willingness to lend is a modest positive signal of insider commitment, but the need for external capital suggests ongoing operational cash burn with no revenue disclosed.
Price Chart
Executive Summary
Harvard Apparatus Regenerative Technology (HRGN) entered into two bridge loan agreements totaling $400,000 with its Chairman and CEO, Junli He. The loans carry an 8% interest rate, mature in May 2027 and July 2027 respectively, and are convertible into equity at the lender's option upon a future qualified financing of at least $5,000,000. This related-party borrowing signals the company is funding operations through insider loans while seeking a larger capital raise, reflecting ongoing cash constraints for this micro-cap OTC-listed company.
Key Financial Metrics
Key Facts
- Company borrowed $400,000 in aggregate from Chairman/CEO Junli He via two bridge notes (May 8, 2026 and July 16, 2026)
- Each note carries 8% fixed annual interest and matures one year from issuance (May 2027 and July 2027)
- Principal and accrued interest may be converted into equity at the lender's option upon a future capital raise of at least $5,000,000
- The loans are related-party transactions approved by disinterested board members
- Company is seeking a capital raise of at least $5,000,000 to repay the notes
Financial Impact
$400,000 in new debt from insider loans at 8% interest, convertible into equity upon a $5M+ capital raise
Risk Factors
- Dilution from conversion of bridge notes into equity upon future capital raise
- Inability to secure $5M+ capital raise could lead to default on notes
- Related-party loan structure may mask true cost of capital
- No revenue or operational update provided in filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-025423 |
| Exhibit: ex_996519.htm | 0001437749-26-025423 |
| Exhibit: ex_996518.htm | 0001437749-26-025423 |
| Document: 0001437749-26-025423-index-headers.html | 0001437749-26-025423 |
| Document: 0001437749-26-025423-index.html | 0001437749-26-025423 |
| Document: 0001437749-26-025423.txt | 0001437749-26-025423 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 6w ago | 8-K | $1.96 $2.12 | ▼ −8.16% | ▼ −5.65% | $1.96 (−0.10%) |
Aug 3, 2026 12w ago | 8-K | $1.00 $1.58 | ▼ −58.00% | ▼ −56.76% | $1.96 (−96.20%) |
Apr 28, 2026 25w ago | 8-K | $1.57 $1.30 | ▼ −17.04% | ▼ −23.09% | $1.96 (+25.21%) |
Apr 15, 2026 27w ago | 8-K | $1.57 $1.50 | ▼ −4.58% | ▼ −10.40% | $1.96 (+24.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers